Alkermes reports encouraging data from Phase III study of Lumryz

Alkermes has reported positive top line data from the Phase III REVITALYZ study, assessing the investigational use of extended-release Lumryz oral suspension in adults with IH. During the open-label dose titration and stable dose periods, all participants received Lumryz, showing improved ESS scores. IH is a rare neurological sleep disorder marked by excessive daytime sleepiness despite normal sleep durations. Credit: Tero Toa55 / Shutterstock.com. Alkermes has reported positive top line data from the Phase III REVITALYZ study, assessing the investigational use of extended-release Lumryz (sodium oxybate) oral suspension in adults with idiopathic hypersomnia (IH). IH is a rare neurological sleep…

Source: Clinical Trials Arena